We have extended the lifespan of our research strategy from spring 2026 to spring 2028, to align our organisational and research strategies. We fund research that covers the causes, consequences and effects of the most prevalent arthritis conditions, and those that have the highest impacts on people. We will also support those conditions most frequently associated with arthritis. We do not actively exclude any areas of arthritis-related research. We will prioritise our investments to ensure that we maintain a varied and balanced research awards portfolio that covers the most prevalent arthritis conditions as well as rarer conditions.